Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and GM.CD40L Vaccine in Lung Adenocarcinoma
NCT02466568Phase 2Withdrawn
- Sponsor
- Moffitt Cancer Center
- Start
- Jul 2018
- Primary completion
- Jul 2019
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
01
Overview
A Phase 2 trial of GM.CD40L in lung adenocarcinoma, sponsored by Moffitt Cancer Center. Planned start Jul 2018; status: withdrawn.
02
Drugs
GM.CD40L
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT02466568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02466568.